Skip to main content

Peer Review reports

From: A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

Original Submission
4 Oct 2020 Submitted Original manuscript
17 Jan 2021 Author responded Author comments - Chih-Hsi Kuo
30 Oct 2020 Reviewed Reviewer Report
2 Nov 2020 Reviewed Reviewer Report
3 Nov 2020 Reviewed Reviewer Report
16 Nov 2020 Reviewed Reviewer Report
26 Nov 2020 Reviewed Reviewer Report
27 Nov 2020 Reviewed Reviewer Report
28 Nov 2020 Reviewed Reviewer Report - Tetsuhiko Asao
2 Dec 2020 Reviewed Reviewer Report
Resubmission - Version 2
17 Jan 2021 Submitted Manuscript version 2
19 Feb 2021 Author responded Author comments - Chih-Hsi Kuo
31 Jan 2021 Reviewed Reviewer Report
23 Jan 2021 Reviewed Reviewer Report
29 Jan 2021 Reviewed Reviewer Report - Tetsuhiko Asao
25 Jan 2021 Reviewed Reviewer Report
Resubmission - Version 3
19 Feb 2021 Submitted Manuscript version 3
1 Mar 2021 Author responded Author comments - Chih-Hsi Kuo
26 Feb 2021 Reviewed Reviewer Report
Resubmission - Version 4
1 Mar 2021 Submitted Manuscript version 4
Publishing
3 Mar 2021 Editorially accepted
24 Mar 2021 Article published 10.1186/s12885-021-08005-1

You can find further information about peer review here.

Back to article page
\